GoodRx Holdings, Inc.
GDRXHealthcareNASDAQHealth Information Services
Scan Results
Daily timeframeGoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The $1.20B market capitalization puts GDRX squarely in small-cap range for its industry. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Market Cap
$1.20B
Beta
1.60
P/E (TTM)
58.67
P/E (Fwd)
9.88
EPS (TTM)
$0.06
EPS (Fwd)
$0.36
ROE
2.5%
ROA
3.0%
Cash
$296.1M
Total Debt
$539.0M
Free CF
$112.5M
52W Change
-15.5%
Annual Financials
Cash vs Debt
Where GDRX stands vs its 150-day and 200-day moving averages
As of the August 25, 2026 close, GDRX finished 30.80% above its 150-day moving average ($2.63) and 28.84% above its 200-day moving average ($2.67). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is GDRX overbought or oversold?
At the August 25, 2026 close, GDRX's RSI(14) was 53.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, GDRX has $296.1M in cash with $539.0M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $112.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 2.5%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.0% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $766.6M (2022) to $796.9M (2025).
A beta of 1.60 means GDRX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence GoodRx Holdings, Inc.'s trajectory.